Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A

Status: Recruiting
Location: See all (37) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:

• Diagnosis of hemophilia A.

• Patients previously treated for Hemophilia A.

• Patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry.

• No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor.

• Initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis).

• Signed informed consent/assent.

Locations
United States
Alabama
South Alabama Medical Science Foundation
Recruiting
Mobile
Arizona
Banner MD Anderson Cancer Center
Recruiting
Phoenix
California
University California Davis
Recruiting
Davis
Orthopaedic Hospital DBA Orthopaedic Institute for Children
Recruiting
Los Angeles
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders
Recruiting
Orange
Colorado
University of Colorado Hemophilia and Thrombosis Center
Recruiting
Aurora
Washington, D.c.
Georgetown University
Recruiting
Washington
Louisiana
Tulane University
Recruiting
New Orleans
Minnesota
Regents of University of Minnesota
Recruiting
Minneapolis
North Carolina
East Carolina University - Brody School of Medicine
Recruiting
Greenville
Other Locations
Austria
Many locations
Withdrawn
Multiple Locations
Belgium
Many locations
Recruiting
Multiple Locations
Brazil
Many locations
Not yet recruiting
Multiple Locations
Canada
Many locations
Recruiting
Multiple Locations
China
Many locations
Withdrawn
Multiple Locations
Colombia
Many locations
Recruiting
Multiple Locations
Denmark
Many locations
Recruiting
Multiple Locations
Finland
Many locations
Withdrawn
Multiple Locations
France
Many locations
Withdrawn
Multiple Locations
Germany
Many locations
Recruiting
Multiple Locations
Greece
Many locations
Recruiting
Multiple Locations
Italy
Many locations
Recruiting
Multiple Locations
Japan
Many locations
Recruiting
Multiple Locations
Kuwait
Many locations
Not yet recruiting
Multiple Locations
Luxembourg
Many locations
Not yet recruiting
Multiple Locations
Mexico
Many locations
Not yet recruiting
Multiple Locations
Netherlands
Many locations
Recruiting
Multiple Locations
Norway
Many locations
Not yet recruiting
Multiple Locations
Portugal
Many locations
Not yet recruiting
Multiple Locations
Russian Federation
Many locations
Not yet recruiting
Multiple Locations
Saudi Arabia
Many locations
Not yet recruiting
Multiple Locations
Slovenia
Many locations
Recruiting
Multiple Locations
Spain
Many locations
Recruiting
Multiple Locations
Sweden
Many locations
Recruiting
Multiple Locations
Switzerland
Many locations
Not yet recruiting
Multiple Locations
Taiwan
Many locations
Recruiting
Multiple Locations
United Arab Emirates
Many locations
Not yet recruiting
Multiple Locations
Contact Information
Primary
Bayer Clinical Trials Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937
Backup
For trial location information (Phone Menu Options '3' or '4')
(+)1-888-84 22937
Time Frame
Start Date: October 21, 2019
Estimated Completion Date: March 31, 2027
Participants
Target number of participants: 200
Treatments
Previously treated patient (PTPs) with hemophilia A
Previously treated patients with hemophilia A receiving damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis)。
Related Therapeutic Areas
Sponsors
Leads: Bayer

This content was sourced from clinicaltrials.gov

Similar Clinical Trials